Logo Informatori.Info

 

 

apr27

Novartis' Ilaris awarded three breakthrough badges in the US


Novartis’ Ilaris has picked up three breakthrough designations in the US for potential indications spanning a group of auto inflammatory disorders called Periodic Fever Syndromes or Hereditary Periodic Fevers.

 

The three conditions for which Ilaris is being reviewed are Tumor Necrosis Factor-Receptor Associated Periodic Syndrome (TRAPS) and Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD), and Familial Mediterranean Fever (FMF) not adequately controlled with colchicine.

These diseases cause disabling and recurrent fevers, possibly accompanied by joint pain and swelling, muscle pain and skin rashes, with complications that can be life-threatening. There are currently no approved medicines available to treat TRAPS or HIDS/MKD and very limited options for patients with FMF.

“This is an important day for patients, including many children, who are affected by these serious and debilitating syndromes that have no or limited treatment options,” said David Epstein, Division Head, Novartis Pharmaceuticals. “Ilaris is a promising medicine under review for these conditions, marking our commitment to making a significant difference to the lives of people with rare diseases.”

The Breakthrough Therapy designations were granted based on data from the pivotal Phase III CLUSTER trial, which has also formed the basis for three supplemental Biologic License Applications in the US.

Ilaris was originally approved by US regulators in 2009 to treat two subtypes of a rare autoinflammatory disease called Cryopyrin-Associated Periodic Syndromes: Muckle-Wells syndrome and Familial Cold Autoinflammatory Syndrome, and subsequently for Systemic Juvenile Idiopathic Arthritis in 2013.

27/04/2016 - Categoria: Farmaci - Da: Sh@wn - 359 letture

 

  Commenti

Nessun Commento.

Il tuo Nome
Email
Website
Titolo
Commento
Immagine CAPTCHA
Inserisci il codice

RITORNA ALLA PAGINA PRECEDENTE

Cerca un articolo

Argomenti
Skip Navigation Links.

AIFA

AIISF

Articoli Scientifici

ASL

Associazioni-Sindacati

Auto Aziendale

Aziende Farmaceutiche

British Medical Journal

Codice Strada

Congressi

Contravvenzioni

Dispositivi Medici

Enasarco

Eventi

Eventi ECM

Farmaci

Farmacie

Farmindustria

Faschim

Federaisf

Fonchim

Informatori

Jama

Lancet

New England

Parafarmacie

RSU Aziende

Sanita'

SLF Cobas

);